BioSpace News Archive

Quipt Home Medical Corp. announced that it will host its Q4 and Full Year Fiscal 2022 earnings conference call and audio webcast on Thursday, December 22, 2022 at 10:00 a.m..

Urica Therapeutics, Inc., a Fortress Biotech, Inc. subsidiary company focused on the development and commercialization of pharmaceutical products to treat gout and other conditions associated with hyperuricemia, announced that the Company has expanded its exclusive license agreement with Fuji Yakuhin Co. Ltd. for the development of dotinurad to include the Middle East and North Africa and Turkey territories.

invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, announces that CEO Peter Llewellyn-Davies will present a corporate update during the upcoming Biotech Showcase 2023 meeting in January.

Nexcella, Inc. announced that it has in-licensed BCMA-targeted next-generation CAR-T therapy NXC-201 with 85% overall response rate and 71% complete response/stringent complete response at the therapeutic dose from the first 20 patients in an ongoing phase 1b relapsed/refractory multiple myeloma ongoing clinical trial as of June 27, 2022 data cutoff with a median of 6 prior lines of therapy.